Focused on developing novel oncology-focused antibody therapeutics against series of targets that modulate elements at the boundary of the innate and adaptive immune systems
- Year invested 2014
- Investment Stage Early
- Sectors
- Investment Status Current
- Website labcentral.org/resident-companies/surface-oncology/
- Company Status Private